J. Yale, G. Bakris, Bertrand Cariou
Mar 28, 2013
Citations
23
Influential Citations
455
Citations
Quality indicators
Journal
Diabetes, Obesity & Metabolism
Abstract
Canagliflozin is a sodium glucose co‐transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) ≥30 and <50 ml/min/1.73 m2].